Published • loading... • Updated
Vaxcyte (NASDAQ:PCVX) Reaches New 52-Week High - Here's Why
The vaccine met all primary endpoints and matched or beat Pfizer and Merck comparators, sending Vaxcyte shares up 56.91% in premarket trading.
- On Monday, Vaxcyte shares climbed about 50%, catapulting the company's market value past $12 billion after its experimental VAX-31 vaccine achieved all primary endpoints in the Phase 3 OPUS-1 clinical trial.
- Designed to protect against 31 bacterial strains, VAX-31 enters an $8 billion annual market, directly competing with Pfizer's Prevnar 20 and Merck's Capvaxive for dominance in adult pneumococcal vaccination.
- Researchers confirmed VAX-31 produced immune responses comparable to existing vaccines while proving superior against three unique strains; the vaccine was 'well tolerated' with adverse reactions resolving within 48 hours.
- Leerink Partners analyst David Risinger called the results 'highly impressive,' though VAX-31 missed stricter benchmarks on two strains against Capvaxive, while Mizuho Securities analyst Salim Syed termed the findings a 'near best-case scenario.'
- Vaxcyte expects results from OPUS-2 and OPUS-3 trials in the first half of 2027, with plans to submit a U.S. marketing application to the Food and Drug Administration in the first half of 2028.
Insights by Ground AI
11 Articles
11 Articles
Coverage Details
Total News Sources11
Leaning Left0Leaning Right2Center5Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
C 71%
R 29%
Factuality
To view factuality data please Upgrade to Premium
